These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Metformin use is associated with a reduced risk of mortality in patients with diabetes hospitalised for COVID-19. Lalau JD; Al-Salameh A; Hadjadj S; Goronflot T; Wiernsperger N; Pichelin M; Allix I; Amadou C; Bourron O; Duriez T; Gautier JF; Dutour A; Gonfroy C; Gouet D; Joubert M; Julier I; Larger E; Marchand L; Marre M; Meyer L; Olivier F; Prevost G; Quiniou P; Raffaitin-Cardin C; Roussel R; Saulnier PJ; Seret-Begue D; Thivolet C; Vatier C; Desailloud R; Wargny M; Gourdy P; Cariou B; Diabetes Metab; 2021 Sep; 47(5):101216. PubMed ID: 33309936 [TBL] [Abstract][Full Text] [Related]
6. Metformin use before COVID-19 vaccination and the risks of COVID-19 incidence, medical utilization, and all-cause mortality in patients with type 2 diabetes mellitus. Yen FS; Wang SI; Lin SY; Wei JC Diabetes Res Clin Pract; 2023 Jun; 200():110692. PubMed ID: 37156428 [TBL] [Abstract][Full Text] [Related]
7. Cardiovascular safety of glucose-lowering agents as add-on medication to metformin treatment in type 2 diabetes: report from the Swedish National Diabetes Register. Ekström N; Svensson AM; Miftaraj M; Franzén S; Zethelius B; Eliasson B; Gudbjörnsdottir S Diabetes Obes Metab; 2016 Oct; 18(10):990-8. PubMed ID: 27282621 [TBL] [Abstract][Full Text] [Related]
8. Important differences in the durability of glycaemic response among second-line treatment options when added to metformin in type 2 diabetes: a retrospective cohort study. Mamza J; Mehta R; Donnelly R; Idris I Ann Med; 2016; 48(4):224-34. PubMed ID: 26982210 [TBL] [Abstract][Full Text] [Related]
9. What next after metformin? A retrospective evaluation of the outcome of second-line, glucose-lowering therapies in people with type 2 diabetes. Morgan CL; Poole CD; Evans M; Barnett AH; Jenkins-Jones S; Currie CJ J Clin Endocrinol Metab; 2012 Dec; 97(12):4605-12. PubMed ID: 23076348 [TBL] [Abstract][Full Text] [Related]
10. Progression to insulin therapy among patients with type 2 diabetes treated with sitagliptin or sulphonylurea plus metformin dual therapy. Inzucchi SE; Tunceli K; Qiu Y; Rajpathak S; Brodovicz KG; Engel SS; Mavros P; Radican L; Brudi P; Li Z; Fan CP; Hanna B; Tang J; Blonde L Diabetes Obes Metab; 2015 Oct; 17(10):956-64. PubMed ID: 25962401 [TBL] [Abstract][Full Text] [Related]
12. Diabetes medications and associations with Covid-19 outcomes in the N3C database: A national retrospective cohort study. Bramante CT; Johnson SG; Garcia V; Evans MD; Harper J; Wilkins KJ; Huling JD; Mehta H; Alexander C; Tronieri J; Hong S; Kahkoska A; Alamgir J; Koraishy F; Hartman K; Yang K; Abrahamsen T; Stürmer T; Buse JB; PLoS One; 2022; 17(11):e0271574. PubMed ID: 36395143 [TBL] [Abstract][Full Text] [Related]
13. Effects of metformin use on total mortality in patients with type 2 diabetes and chronic obstructive pulmonary disease: A matched-subject design. Yen FS; Chen W; Wei JC; Hsu CC; Hwu CM PLoS One; 2018; 13(10):e0204859. PubMed ID: 30286138 [TBL] [Abstract][Full Text] [Related]
14. Is metformin use associated with low mortality in patients with type 2 diabetes mellitus hospitalized for COVID-19? a multivariable and propensity score-adjusted meta-analysis. Ma Z; Krishnamurthy M PLoS One; 2023; 18(2):e0282210. PubMed ID: 36821577 [TBL] [Abstract][Full Text] [Related]
15. Preadmission metformin use and mortality among intensive care patients with diabetes: a cohort study. Christiansen C; Johansen M; Christensen S; O'Brien JM; Tønnesen E; Sørensen H Crit Care; 2013 Sep; 17(5):R192. PubMed ID: 24018017 [TBL] [Abstract][Full Text] [Related]
16. Association between first-line monotherapy with sulphonylurea versus metformin and risk of all-cause mortality and cardiovascular events: a retrospective, observational study. Morgan CL; Mukherjee J; Jenkins-Jones S; Holden SE; Currie CJ Diabetes Obes Metab; 2014 Oct; 16(10):957-62. PubMed ID: 24720708 [TBL] [Abstract][Full Text] [Related]
17. Association of metformin with mortality or ARDS in patients with COVID-19 and type 2 diabetes: A retrospective cohort study. Jiang N; Chen Z; Liu L; Yin X; Yang H; Tan X; Wang J; Li H; Tian M; Lu Z; Xiong N; Gong Y Diabetes Res Clin Pract; 2021 Mar; 173():108619. PubMed ID: 33310173 [TBL] [Abstract][Full Text] [Related]
18. Epidemiology of lactic acidosis in type 2 diabetes patients with metformin in Japan. Chang CH; Sakaguchi M; Dolin P Pharmacoepidemiol Drug Saf; 2016 Oct; 25(10):1196-1203. PubMed ID: 27221971 [TBL] [Abstract][Full Text] [Related]
19. Metformin use and risk of COVID-19 among patients with type II diabetes mellitus: an NHIS-COVID-19 database cohort study. Oh TK; Song IA Acta Diabetol; 2021 Jun; 58(6):771-778. PubMed ID: 33582839 [TBL] [Abstract][Full Text] [Related]
20. Is there an association between metformin use and clinical outcomes in diabetes patients with COVID-19? Do JY; Kim SW; Park JW; Cho KH; Kang SH Diabetes Metab; 2021 Jul; 47(4):101208. PubMed ID: 33160030 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]